-
2024-516873-57-00
10
2026-01-13
Acute myeloid leukemia in adults aged 18 to 60
-
2025-522598-12-00
10
2025-12-17
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
-
2025-521249-25-00
7
2025-10-30
MTAP-deleted advanced or metastatic solid tumors
-
2023-508827-10-00
4
2025-10-13
Patients with primary operable stage II, grade 2 or 3, Ki67 #20%, HR+/
-
2025-521681-10-00
4
2025-10-02
Lung Cancer
-
2025-521115-40-00
4
2025-09-30
Advanced or Metastatic Non-small Cell Lung Cancer
-
2023-510479-72-00
3
2025-08-05
Relapsed/Refractory AML or Higher-Risk MDS
-
2024-517817-34-00
9
2025-06-18
Gastric Cancer
-
2024-517818-15-00
9
2025-06-06
Non-Small Cell Lung Cancer
-
2024-512504-19-00
1
2025-05-28
solid tumors
-
2024-513307-13-00
4
2025-05-26
Advanced/metastatic solid tumors including gynecological
cancers (endo
-
2023-506842-22-00
7
2025-05-19
Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian
-
2024-512925-95-00
5
2025-05-16
Advanced/Metastatic Breast Cancer
-
2024-516733-12-00
1
2025-05-13
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorect
-
2024-513968-25-00
5
2025-04-28
Metastatic castration-resistant prostate cancer (mCRPC)
-
2024-516063-89-00
5
2025-04-10
Metastatic Pancreatic Ductal Adenocarcinoma
-
2024-517416-30-00
10
2025-03-31
Gastrointestinal Cancers
-
2024-515740-23-00
5
2025-03-25
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-517114-15-00
7
2025-03-07
newly diagnosed gliblastoma
-
2024-511253-21-00
3
2025-02-28
Thoracic tumors with homozygous MTAP-deletion
-
2024-512998-27-00
5
2025-02-21
Non-Small Cell Lung Cancer
-
2023-510004-49-00
4
2025-02-18
non pretreated metastatic PAncreatic Cancer
-
2024-511650-50-00
5
2025-01-17
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2024-511957-23-00
5
2025-01-03
Recurrent or Persistent Endometrial Cancer